Credit Suisse Downgrades Hayward Holdings to Neutral
Credit Suisse analyst Daniel Oppenheim downgrades Hayward Holdings (NYSE:HAYW) from Outperform to Neutral.
Credit Suisse Downgrades AZEK Co to Neutral
Credit Suisse analyst Daniel Oppenheim downgrades AZEK Co (NYSE:AZEK) from Outperform to Neutral.
Guggenheim Downgrades Relmada Therapeutics to Neutral
Guggenheim analyst Yatin Suneja downgrades Relmada Therapeutics (NASDAQ:RLMD) from Buy to Neutral.
B of A Securities Downgrades Organon to Underperform, Lowers Price Target to $25
B of A Securities analyst Jason Gerberry downgrades Organon (NYSE:OGN) from Neutral to Underperform and lowers the price target from $37 to $25.
Baird Downgrades Beacon Roofing Supply to Neutral, Lowers Price Target to $65
Baird analyst David Manthey downgrades Beacon Roofing Supply (NASDAQ:BECN) from Outperform to Neutral and lowers the price target from $77 to $65.
Piper Sandler Downgrades Berkshire Hills Bancorp to Underweight, Lowers Price Target to $29
Piper Sandler analyst Mark Fitzgibbon downgrades Berkshire Hills Bancorp (NYSE:BHLB) from Neutral to Underweight and lowers the price target from $31 to $29.
RBC Capital Downgrades Ardagh Metal Packaging to Sector Perform, Lowers Price Target to $5
RBC Capital analyst Arun Viswanathan downgrades Ardagh Metal Packaging (NYSE:AMBP) from Outperform to Sector Perform and lowers the price target from $7 to $5.
Canaccord Genuity Downgrades T2 Biosystems to Hold, Adjusts Price Target to $2.5
Canaccord Genuity analyst Kyle Mikson downgrades T2 Biosystems (NASDAQ:TTOO) from Buy to Hold and adjusts the price target from $12.5 to $2.5.
Piper Sandler Downgrades Otonomy to Neutral, Lowers Price Target to $0.5
Piper Sandler analyst Christopher Raymond downgrades Otonomy (NASDAQ:OTIC) from Overweight to Neutral and lowers the price target from $3 to $0.5.
Oppenheimer Downgrades Relmada Therapeutics to Perform
Oppenheimer analyst Jay Olson downgrades Relmada Therapeutics (NASDAQ:RLMD) from Outperform to Perform.